Chronic spontaneous urticaria—status quo and future

作者
Susanne Melchers,Jan Peter Nicolay
出处
期刊:Allergo journal international [Springer Nature]
卷期号:32 (8): 326-336 被引量:9
标识
DOI:10.1007/s40629-023-00272-7
摘要

Abstract Chronic spontaneous urticaria (CsU) is a chronic inflammatory dermatosis whose etiology is not yet fully understood. In affected patients, it is often associated with a high limitation of health-related quality of life, which necessitates effective therapeutic management. Different immune cell populations such as mast cells, eosinophilic and basophilic granulocytes, and T cells are involved in the pathogenesis of CsU, whereby mast cells playing a key role. In addition, type I autoallergic reactions with auto IgE antibodies or type IIb autoimmune reactions with auto IgG antibodies have been identified in a proportion of patients. The current international guideline initially recommends the use of second-generation H1 antihistamines, first in standard, then in off-label quadruple dosing. Subsequently, the anti-IgE antibody omalizumab should be added. However, this therapy algorithm does not lead to freedom from manifestations in all patients. Therefore, various targeted therapies are currently being evaluated for their efficacy in CsU, such as off-label use of the anti-interleukin receptor alpha (IL4Rα) antibody dupilumab, the anti-IL-17A antibody secukinumab, or interleukin‑5 blockade using mepolizumab, reslizumab, or benralizumab. In addition, new promising compounds such as the Bruton tyrosine kinase (BTK) inhibitors remibrutinib and fenebrutinib, the anti-cKIT antibody barzolvolimab, the anti-SIGLEC8 antibody lirentelimab, the anti-TSLP antibody tezepelumab, the anti-C5aR1 antibody advoralimab, or the topical application of Syk kinase inhibitors are being tested, which were developed according to new insights into the pathogenesis of CsU. The BTK inhibitor fenebrutinib is currently not being pursued due to a less favorable side effect profile compared to remibrutinib, as well as the anti-IgE antibody ligelizumab, which was inferior to omalizumab therapy in a phase 3 study. Overall, there is a high need for new therapeutic strategies to better treat CsU both symptomatically and curatively. This requires a more comprehensive understanding of pathogenesis of the disease in order to develop new targeted therapies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
小卷完成签到,获得积分10
刚刚
刚刚
Hj发布了新的文献求助10
1秒前
月无痕完成签到 ,获得积分10
1秒前
星星发布了新的文献求助10
1秒前
1秒前
非酋本酋完成签到,获得积分10
1秒前
又双呦灼完成签到,获得积分10
2秒前
sinon完成签到,获得积分10
2秒前
Igniting完成签到,获得积分20
2秒前
活力的香发布了新的文献求助10
2秒前
huhuhu发布了新的文献求助20
3秒前
yang完成签到,获得积分10
3秒前
zyf发布了新的文献求助10
3秒前
123完成签到,获得积分10
3秒前
Markyang发布了新的文献求助10
4秒前
4秒前
4秒前
5秒前
阿飞发布了新的文献求助10
5秒前
5秒前
六六发布了新的文献求助10
5秒前
5秒前
ly完成签到 ,获得积分10
5秒前
屿111完成签到,获得积分10
5秒前
小吃包张张完成签到 ,获得积分10
6秒前
orixero的应助被aaa采纳,获得10
6秒前
7秒前
猫头鹰完成签到 ,获得积分10
7秒前
密林小叶子完成签到,获得积分10
7秒前
ren完成签到,获得积分10
7秒前
在水一方的应助被又双呦灼采纳,获得10
7秒前
樱桃小完犊子完成签到,获得积分10
7秒前
妍妍发布了新的文献求助10
8秒前
Xiyueerr关注了科研通微信公众号
8秒前
单调完成签到 ,获得积分10
8秒前
8秒前
LIUYC发布了新的文献求助10
9秒前
今后的应助被wwwww采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180617
求助须知:如何正确求助?哪些是违规求助? 9570702
关于积分的说明 21813868
捐赠科研通 7776860
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557571
邀请新用户注册赠送积分活动 2479253